Overview
Fe²⁺-Ribavirin is a proposed MDC formulation designed to enhance liver-specific delivery and metabolic retention of ribavirin. Incorporating ferrous ions supports targeting hepatocytes through endogenous iron transport mechanisms, potentially reducing systemic toxicity and dose frequency.
Mechanism of Action
- Fe²⁺ facilitates uptake by hepatocyte transferrin receptors
- Ribavirin remains active as a nucleoside analog antiviral
- Complexation improves intracellular accumulation in hepatic tissue
Key Properties
- Hepatic targeting through iron pathways
- Enhanced metabolic half-life
- Reduced hemolytic side effects
Application
Therapeutic Class: Liver Disease
Applicable for hepatitis B and C treatment protocols, especially in patients with limited tolerance to standard ribavirin formulations.
Antiviral
Hepatic Targeting
Development Stage
Formulation Development
Further Information
To explore licensing, preclinical testing partnerships, or hepatic delivery platform integration, contact our research team.
Contact Us